Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates Pharmaceutical TechnologyBMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year's EHA conference.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaceutical Technology BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: Altaris to acquire Simulations Plus in $375m all-cash deal Related Stories Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome pharminent June 15, 2026 Clinical Data Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease pharminent June 15, 2026
